Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Aviso Wealth Management

Aviso Wealth Management trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 38.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,893 shares of the biopharmaceutical company’s stock after selling 4,248 shares during the period. Aviso Wealth Management’s holdings in Bristol-Myers Squibb were worth $357,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. ETF Store Inc. acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $222,000. AMG National Trust Bank lifted its position in shares of Bristol-Myers Squibb by 4.1% during the 3rd quarter. AMG National Trust Bank now owns 122,403 shares of the biopharmaceutical company’s stock valued at $6,333,000 after acquiring an additional 4,808 shares during the period. Aljian Capital Management LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at approximately $780,000. Prudent Man Advisors LLC raised its position in shares of Bristol-Myers Squibb by 32.3% during the 3rd quarter. Prudent Man Advisors LLC now owns 14,556 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 3,551 shares during the last quarter. Finally, TrinityPoint Wealth LLC raised its position in shares of Bristol-Myers Squibb by 8.7% during the 3rd quarter. TrinityPoint Wealth LLC now owns 6,550 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 522 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Samit Hirawat purchased 1,830 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were acquired at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This trade represents a 3.04 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.

Bristol-Myers Squibb Stock Down 3.9 %

Shares of NYSE BMY opened at $56.22 on Monday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The firm has a fifty day moving average of $52.73 and a 200-day moving average of $47.27. The stock has a market capitalization of $114.02 billion, a PE ratio of -15.66, a P/E/G ratio of 15.23 and a beta of 0.44. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. During the same period in the previous year, the company earned $2.00 EPS. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, analysts anticipate that Bristol-Myers Squibb will post 0.93 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.27%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -66.85%.

Analysts Set New Price Targets

Several brokerages recently issued reports on BMY. Morgan Stanley lifted their price objective on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Finally, Wolfe Research assumed coverage on Bristol-Myers Squibb in a report on Friday. They issued a “peer perform” rating for the company. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, two have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus price target of $54.07.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.